Royalty Stacking in Multi-Patent Therapies: Fairness Concerns

Introduction

Royalty stacking occurs when a single product requires licences from multiple patent holders, and each holder independently demands a royalty. In biotechnology and pharmaceutical industries, a therapy may involve several patents covering the active ingredient, formulation, delivery mechanism, manufacturing process, diagnostic companion, or method of treatment.

When all royalties are added together, the cumulative licensing cost may become excessive. This can reduce the licensee’s profit, increase the price of treatment, discourage investment, and restrict patient access. The concern is particularly significant for complex biologics and combination therapies, where multiple patented technologies may be needed to develop and commercialize one medicine.

Royalty stacking does not automatically make a licence unlawful. The legal issue is whether the cumulative burden results from legitimate patent rights and fair negotiations or from anticompetitive conduct, contractual abuse, or unreasonable licensing terms.

Fairness and Legal Concerns

1. Cumulative royalty burden: Each patent owner may demand a reasonable royalty when considered individually. However, the combined amount may exceed the economic value of the final therapy. This can make development commercially unviable.

2. Access to essential medicines: Excessive royalty demands may be passed on to patients through higher prices. In India, this raises concerns under the public-interest objectives of the Patents Act, 1970, including access to medicines and prevention of unreasonable restrictions on patent use.

3. Patent thickets and bargaining imbalance: Numerous overlapping patents can make it difficult for a biotechnology company to identify every required licence. Patent holders may use their position to delay negotiations or demand disproportionate payments.

4. Innovation and investment: Excessive cumulative royalties can discourage follow-on research, particularly by smaller biotech companies and university spin-offs. Yet royalties also reward genuine innovation and help finance future research. Fairness therefore requires balancing access with incentives for invention.

The US Federal Trade Commission and Department of Justice have described royalty stacking as a situation in which multiple patent burdens may collectively make production unprofitable or impede innovation. They also recognize that patent pools and portfolio cross-licensing may reduce transaction costs and cumulative burdens.

Federal Trade Commission+2

Relevant Case Laws

1. United States v. Line Material Co., 333 U.S. 287 (1948)

The US Supreme Court considered cross-licensing and royalty sharing involving complementary patents. It recognized that agreements between holders of mutually dependent patents may be necessary to overcome patent deadlock and enable commercial use of the combined technology. The case supports the principle that coordinated licensing can sometimes resolve overlapping patent barriers. However, it does not establish that all royalty-sharing arrangements are lawful; their purpose and effect remain relevant.

Justia U.S. Supreme Court Center

2. Microsoft Corp. v. Motorola, Inc., 795 F.3d 1024 (9th Cir. 2015)

The Ninth Circuit addressed the calculation of royalties for standard-essential patents subject to a RAND commitment. It emphasized that royalty assessment must consider the relevant technology and the risk of cumulative royalty burdens. The decision illustrates how a licensing framework can account for aggregate royalties rather than treating each patent in isolation. Although it concerns telecommunications patents, its economic reasoning is relevant by analogy to multi-patent biotech products.

WIPO Lex

3. FTC v. Qualcomm Inc., 969 F.3d 974 (9th Cir. 2020)

The Ninth Circuit rejected the FTC’s antitrust challenge to Qualcomm’s licensing practices, finding that the FTC had not established the required anticompetitive harm under the applicable legal standard. The judgment cautions that high or disputed royalty rates do not automatically amount to an antitrust violation. Evidence of exclusionary conduct and its competitive effects is important.

Justia Law

Indian Legal Framework

Under the Patents Act, 1970:

Section 84 permits compulsory licensing after the prescribed period where statutory grounds are met, including failure to meet reasonable public requirements, lack of affordability, or non-working of the patent in India.

Section 90 requires consideration of reasonable royalty and other relevant factors when settling compulsory-licence terms.

Section 3(d) restricts patentability of certain new forms of known substances unless the statutory requirements are met, helping prevent unjustified extension of patent protection.

In Bayer Corporation v. Union of India, 2014 (60) PTC 277 (Bom), the Bombay High Court upheld the compulsory licence for sorafenib. The case demonstrates that patent rights and royalty payments may be balanced against affordability and public access to medicines.

Indian Kanoon+1

Conclusion

Royalty stacking in multi-patent therapies raises important fairness concerns because several individually valid patent claims may collectively impose an excessive burden. The law must balance the legitimate reward of patent holders against affordable access, competition, and continued biotechnology innovation.

Possible solutions include patent pools, portfolio licensing, cross-licensing, transparent royalty calculations, and competition-law scrutiny where there is evidence of exclusionary conduct. In India, compulsory licensing provides a statutory mechanism for addressing certain public-interest concerns. The central principle is that royalties should reward genuine innovation without allowing cumulative licensing burdens to unnecessarily obstruct the development or availability of important therapies.